Trinity Biotech plc (TRIB) Stock Forecast & Price Target

Trinity Biotech plc (TRIB) has an ST Score of 41.1 (C), on our 0–100 scale where higher is stronger. The ST Score combines eight factor grades — valuation, profitability, financial strength, momentum, growth, forecast, sentiment and Piotroski — into a single A+ to F rating.

Analysts rate TRIB a Buy. Our ST Score grades it C (41.1/100). The ST Score is a data-driven signal, not a recommendation.

Valuation B, Profitability C+, Financial Strength C, Momentum D-, Growth C+.

Trinity Biotech plc (TRIB) earns a valuation grade of B, measured against Medical - Specialties peers. The valuation factor looks at multiples such as P/E, P/S, P/B, EV/EBITDA and free cash flow yield.

Trinity Biotech plc (TRIB) earns a growth grade of C+, measured against Medical - Specialties peers. The growth factor looks at revenue, earnings and cash flow growth over recent quarters and years.

Trinity Biotech plc (TRIB) earns a profitability grade of C+, measured against Medical - Specialties peers. The profitability factor looks at margins and returns such as gross margin, net margin, ROE and ROIC.

Trinity Biotech plc (TRIB) earns a financial strength grade of C, measured against Medical - Specialties peers. The financial strength factor looks at debt levels, liquidity and coverage ratios.

Trinity Biotech plc (TRIB) has a Piotroski F-Score of 3 out of 9. The Piotroski score checks nine accounting signals covering profitability, leverage and operating efficiency; scores of 8–9 are considered strong and 0–2 weak.